Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time

被引：71

作者：

Van Os, G. M. A. ^{[1
,2
]}

De Laat, B. ^{[1
,3
,4
]}

Kamphuisen, P. W. ^{[5
]}

Meijers, J. C. M. ^{[2
,5
]}

De Groot, Ph. G. ^{[1
]}

机构：

[1] Univ Med Ctr, Lab Clin Chem & Haematol, Utrecht, Netherlands

[2] Univ Amsterdam, Acad Med Ctr, Dept Expt Vasc Med, NL-1012 WX Amsterdam, Netherlands

[3] Maastricht Univ Med Ctr, CARIM, Maastricht, Netherlands

[4] Sanquin Res, Amsterdam, Netherlands

[5] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2011年 / 9卷 / 08期

关键词：

FACTOR-XA INHIBITOR; ANTIPHOSPHOLIPID SYNDROME; ANTIBODIES; THROMBOSIS; UPDATE;

D O I：

10.1111/j.1538-7836.2011.04395.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1657 / 1659

页数：3

共 12 条

[1] PARADOXIC EFFECT OF MULTIPLE MILD COAGULATION-FACTOR DEFICIENCIES ON THE PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME [J].

BURNS, ER ;

GOLDBERG, SN ;

WENZ, B .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1993, 100 (02) :94-98

[2] Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? [J].

Cohen, H. ;

Machin, S. J. .

LUPUS, 2010, 19 (04) :486-491

[3] IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis [J].

de Laat, B ;

Derksen, RHWM ;

Urbanus, RT ;

de Groot, PG .

BLOOD, 2005, 105 (04) :1540-1545

[4] Towards evidence-based treatment of thrombotic antiphospholipid syndrome [J].

Derksen, R. H. W. M. ;

de Groot, P. G. .

LUPUS, 2010, 19 (04) :470-474

[5] Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature [J].

Galli, M ;

Luciani, D ;

Bertolini, G ;

Barbui, T .

BLOOD, 2003, 101 (05) :1827-1832

[6] Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity [J].

Graff, Jochen ;

von Hentig, Nils ;

Misselwitz, Frank ;

Kubitza, Dagmar ;

Becka, Michael ;

Breddin, Hans-Klaus ;

Harder, Sebastian .

JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (11) :1398-1407

[7] Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects [J].

Kubitza, D ;

Becka, M ;

Wensing, G ;

Voith, B ;

Zuehlsdorf, M .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (12) :873-880

[8] Rivaroxaban and false positive lupus anticoagulant testing [J].

Merriman, Eileen ;

Kaplan, Zane ;

Butler, Jenny ;

Malan, Erica ;

Gan, Eng ;

Huyen Tran .

THROMBOSIS AND HAEMOSTASIS, 2011, 105 (02) :385-386

[9] International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) [J].

Miyakis, S ;

Lockshin, MD ;

Atsumi, T ;

Branch, DW ;

Brey, RL ;

Cervera, R ;

Derksen, RHWM ;

De Groot, PG ;

Koike, T ;

Meroni, PL ;

Reber, G ;

Shoenfeld, Y ;

Tincani, A ;

Vlachoyiannopoulos, PG ;

Krilis, SA .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) :295-306

[10] The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants [J].

Moore, GW ;

Smith, MP ;

Savidge, GF .

BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 (03) :307-312

← 1 2 →